<DOC>
	<DOCNO>NCT01598168</DOCNO>
	<brief_summary>Heparin anticoagulant ( blood thinner ) commonly use treat patient heart attack patient blood clot legs lung ( venous thrombosis ) . Some patient develop allergic reaction heparin , condition call heparin-induced thrombocytopenia ( HIT ) . HIT make blood clot , opposite heparin design . These blood clot lead heart attack , stroke , limb amputation , death . The objective 200 patient study determine new blood thinner call rivaroxaban ( Xarelto ) use treat HIT . Rivaroxaban take mouth , require blood testing , low risk bleeding use treat blood clot clinical trial . If study show rivaroxaban use treat HIT , two important benefit . For patient HIT , benefit safe , easy-to-use drug protect develop life limb-threatening blood clot . For Canadian health care system , benefit drug much less expensive drug currently use treat HIT .</brief_summary>
	<brief_title>Rivaroxaban Treatment Patients With Suspected Confirmed Heparin-Induced Thrombocytopenia</brief_title>
	<detailed_description>Consecutive adult patient intermediate high clinical probability HIT ( accord clinical prediction rule call `` 4T 's Score ) receive rivaroxaban 15 mg bid await confirmation exclusion HIT local laboratory assay . Patients confirm HIT local laboratory assay continue receive rivaroxaban 15 mg bid platelet count â‰¥ 150 end study ( Day 30 ) . At time platelet count recovery ( typically 4-7 day ) , transition maintenance dose rivaroxaban ( 20 mg od ) maximum 30 day .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Adult patient 4T 's Score great equal 4 . Require ongoing anticoagulant therapy mechanical heart valve . Severe renal insufficiency ( CrCl &lt; 30 ml/min ) Hepatic disease ( include ChildPugh B C ) associate coagulopathy clinically relevant bleeding risk Inability take oral medication . Ongoing requirement systemic treatment azoleantimycotics ( except fluconazole ) HIVprotease inhibitor strong CYP3A4 inducer Clinically significant active bleeding lesion increase risk bleeding within last 6 month Platelet count le 80 ongoing need antiplatelet therapy may exclude discretion investigator Pregnant woman childbearing potential use adequate birth control method Hypersensitivity rivaroxaban ingredient formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>rivaroxaban</keyword>
	<keyword>treatment</keyword>
	<keyword>venous thromboembolism</keyword>
	<keyword>arterial thromboembolism</keyword>
	<keyword>thrombocytopenia</keyword>
</DOC>